Kura Oncology to Participate in Two Upcoming Investor Conferences
28 févr. 2022 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
24 févr. 2022 16h03 HE
|
Kura Oncology, Inc.
– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase...
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
17 févr. 2022 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
10 févr. 2022 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Expands Leadership Team with Key Promotions
01 févr. 2022 16h01 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
16 déc. 2021 09h16 HE
|
Kura Oncology, Inc.
– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC – – Combination has potential to address up to 50% of patients with HNSCC – – Initial cohort comprised of patients with...
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
13 déc. 2021 10h30 HE
|
Kura Oncology, Inc.
– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma – – Results presented at ASH underscore potential of...
Kura Oncology to Participate in Two Upcoming Investor Conferences
23 nov. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Third Quarter 2021 Financial Results
04 nov. 2021 16h05 HE
|
Kura Oncology, Inc.
– Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML – – ASH presentation to highlight molecular mechanisms of activity for...
Kura Oncology to Report Third Quarter 2021 Financial Results
28 oct. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...